Effects of GLP-1 Receptor Agonists on Major Cardiovascular Events Among Patients with Atopic Dermatitis: A Population-Based Study

Feb 6, 2026Dermatitis : contact, atopic, occupational, drug

GLP-1 Receptor Agonists and Risk of Major Heart Problems in Patients with Atopic Dermatitis

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Among 24,936 patients with atopic dermatitis who used GLP-1 receptor agonists, lower odds of major adverse cardiovascular events were observed at 20 years.

Patients with atopic dermatitis on GLP-1 receptor agonists had reduced odds of cerebrovascular disease.
A decrease in heart failure incidence was noted in patients using GLP-1 receptor agonists.
The use of GLP-1 receptor agonists was associated with a lower occurrence of atherosclerosis.
Ischemic heart disease rates were also reduced among patients with atopic dermatitis taking GLP-1 receptor agonists.
These findings suggest potential cardiometabolic benefits of GLP-1 receptor agonists for patients with atopic dermatitis.

AI simplified

Atopic dermatitis (AD) is linked to increased cardiovascular risk. While GLP-1 receptor agonists (GLP-1RAs) show cardiometabolic benefits in the general population, their impact in patients with AD remains unclear.To evaluate whether GLP-1RA use is associated with a reduced risk of major adverse cardiovascular events (MACE) in patients with AD.This retrospective cohort study used TriNetX Research Network. Patients with AD ≥12 years old who used GLP-1RAs between April 2005 and December 2020 were 1:1 propensity-score matched to patients with AD not on GLP-1RA by demographic and cardiovascular risk factors. The primary outcome was incidence of MACE (cerebrovascular disease [CVD], heart failure [HF], atherosclerosis, ischemic heart disease [IHD], and percutaneous coronary intervention [PCI]) at 5, 10, and 20 years post-index date.Of the 547,246 patients with AD, 24,936 (4.6%) used GLP-1RAs. After propensity-matching, at 20 years, patients with AD on GLP-1RA had lower odds of CVD (adjusted odds ratio [aOR] 0.718 [0.643-0.800]), HF (aOR 0.791 [0.732-0.854]), atherosclerosis (aOR 0.768 [0.715-0.826]), and IHD (aOR 0.900 [0.841, 0.963]), compared with patients with AD not using GLP-1RAs.In patients with AD, GLP-1RA use was associated with a reduced long-term risk of CVD, HF, IHD, and atherosclerosis, highlighting their potential cardiometabolic benefit in this population. Background: Objective: Methods: Results: Conclusions:

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Effects of GLP-1 Receptor Agonists on Major Cardiovascular Events Among Patients with Atopic Dermatitis: A Population-Based Study

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief